Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 48 49 50

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Selexys Pharmaceuticals–Novartis: investment, 201611 acquisition by Novartis for up to $665m upfront + acquisition + milestone payments 2012-01-01
Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi 2012-01-01
Vivacta–Novartis: investment, 2012 acquisition by Novartis 2012-01-01
Xiril–Sias: investment, 2012 acquisition of Xiril AG by Sias AG 2012-01-01
Metrohm–Analytik Jena: analytical instruments, 2011–201312 distribution Metrohm India Ltd excl sales partner for AJ products in India 2011-11-01
Acacia Pharma–Gilde Investment: investment, 201103 financing round Series A totalling $10m incl existing investor Gilde Healthcare 2011-03-31
Acacia Pharma–Lundbeck: investment, 201103 financing round Series A totalling $10m incl new investor Lundbeckfond Ventures 2011-03-31
Acacia Pharma–SEVERAL: investment, 201103 financing round Series A $10m from new investor Lundbeckfond Ventures + existing investor Gilde Healthcare 2011-03-31
Genoptix–Novartis: investment, 201701–201703 DIVESTMENT sale €na of Genoptix (excl biopharma business) to Ampersand + 1315 Capital + new managers 2011-01-24
AVISO GmbH–ALS Automated Lab Solutions: investment, 2011 newly found ALS acquires all assets of AVISO keeping core team intact 2011-01-01
Dr. Falk Pharma–Zedira: transglutaminase inhibitor, 2011– license to ZED1227 in Europe plus joint ownership of rights outside Europe 2011-01-01
JnJ–Molecular Partners: DARPins, 2011–201610 collab + license DARPin targeting IL-13 + IL-17 against pulmonary disease TERMINATED 10/16 2011-01-01
Meiji Seika Kaisha–Newron: safinamide, 2011– license to develop + manufacture + commercialise safinamide in Asia to Meiji Seika Pharma 2011-01-01
Pfizer–KKR: investment, 2011 acquisition of Capsugel from Pfizer by KKR 2011-01-01
Rebiotix–SEVERAL: investment, 2011 seed financing round $5m 2011-01-01
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Poxel–LCF Rothschild: investment, 201007 financing round Series A totalling €16m incl lead investor EdRIP 2010-07-08
Roche–Novimmune: therapeutic antibody, 201007– excl license to discover + develop ABs targeting IL-17 pathway for autoimmune diseases Genentech 2010-07-01
Nepentes–Sanofi-Aventis: investment, 201005 acquisition of Nepentes SA tender offer €105m 2010-05-19
Catherex–Medigene: investment, 201004 spin-off of Catherex from Medigene with Medigene receiving 40% shareholding in Catherex 2010-04-01
Ablynx–Hoffmann Eitle: legal services, 2010–201501 representation of Ablynx in patent dispute w Domantis by Hoffmann Eitle Munich 2010-01-01
China National Nuclear–ITM: radiopharmaceuticals, 2010– collab strategic partnership with CIRC in China 2010-01-01
Probiodrug–Bellevue: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Biogen Idec: investment, 200911 financing round Series B totalling €36m incl new + co-investor Biogen Idec New Ventures 2009-11-02
Probiodrug–LCF Rothschild: investment, 200911 financing round Series B totalling €36m incl new + lead investors BB Biotech + EdRIP 2009-11-02
Probiodrug–Life Sciences Partners: investment, 200911 financing round Series B totalling €36m incl new + co-investor LSP 2009-11-02
Denali Therapeutics–Evotec: CNS drug discovery, 201608 strategic collab existent 2008-08-25
Denali Therapeutics–Roche: LRRK2 inhibitors, 201608 license ww excl existent to develop + commericalize LRRK2 inhibitors from Genentech 2008-08-25
BioNTech–SEVERAL: investment, 2008 seed financing round 2008-01-01
Isoprime–Elementar: investment, 2008 acquisition of Isoprime Ltd by Elementar Analysensysteme GmbH 2008-01-01
KLIFO–PERSON: investment, 2008 acquisition of KLIFO A/S by Alejandra Mørk who joins as CEO 2008-01-01
Roche–AC Immune: therapeutic antibodies, 2006– license excl for anti-Abeta program to Genentech 2006-01-01
Umetrics–MKS Instruments: investment, 2006 acquisition by MKS Instruments 2006-01-01
Actelion–Enamine: chemical compound library, 2005– collab supply of screening compound library to Actelion 2005-01-01
Chandler Instruments–AMETEK: investment, 2003 acquisition of Chandler Instruments by AMETEK 2003-01-01
Grabner Instruments–Chandler Instruments: investment, 2002 acquisition of Grabner by Chandler 2002-01-01
Biocentric–Hain Lifescience: molecular diagnostics, 2001– exclusive distributor of Hain products in France 2001-01-01
Selexis–SEVERAL: investment, 2001 seed financing CHF100k 2001-01-01
Boehringer Mannheim–Roche: investment, 1998 acquisition by Roche 1998-01-01
Eurofins–SEVERAL: investment, 199710 IPO 1997-10-24
Hoechst–Clariant: investment, 1997 acquisition of Hoechst Speciality Chemical Business by Clariant 1997-01-01
Brechbühler–Phenomenex: chromatography consumables, 1991–201708 distribution in Switzerland by Brechbühler TERMINATED 9/17 1991-01-01
Columbus Pharmaceutical–Boehringer: investment, 1978 acquistion by Boehringer + renamed Roxane Laboratories Inc 1978-01-01
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series A CHF0.5m
Cellestia Biotech–SEVERAL: investment, <2017 seed financing round Series B CHF2.3m
Mind NRG–Minerva Neurosciences: investment, before 202008 acquisition of Mind NRG (CH) by Minerva Neurosciences
OTHER–Novartis: investment, 201401 acquisition of biologics manufacturing faciltiy in Longmont CO by AveXis
next pagenext page 1 2 3 ... 48 49 50



Advertisement

Picture [iito] Fighting Customers 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Campus Berlin-Buch GmbH BBC BerlinBioCube Start-up Center 650x300px

» top